Welcome to our dedicated page for BIOMERICA SEC filings (Ticker: BMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biomerica SEC filings document governance, stockholder voting and capital-plan matters for the medical diagnostics company. Annual proxy materials and Form 8-K reports cover director elections, board size and committee composition, independent director appointments, advisory votes on executive compensation, auditor ratification and amendments to the company’s stock incentive plan.
The filings also record common-stock voting mechanics, annual meeting results and Nasdaq-related independence determinations, providing formal disclosure around Biomerica’s board oversight, executive compensation framework and equity incentive authorization.
Biomerica, Inc. (BMRA) reported a net loss of $4,973,000 for fiscal 2025 compared with a $5,978,000 loss in fiscal 2024, showing an improvement in operating results. The company had cash and cash equivalents of approximately $2,399,000 and working capital of about $3,135,000 at May 31, 2025, versus $4,170,000 cash and $5,527,000 working capital a year earlier, indicating reduced liquidity. During the year the company completed ATM sales of 440,687 shares for gross proceeds of ~$2,143,000 and net proceeds of ~$2,015,000. Revenue mix included over-the-counter sales of $1,049,000 and contract manufacturing of $1,070,000, with two distributors accounting for 41% of net sales in 2025. The company’s common stock trades on the Nasdaq Capital Market under the symbol BMRA and a 1-for-8 reverse split became effective April 21, 2025.